Shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) have received an average rating of “Moderate Buy” from the eight research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $22.25.
TGTX has been the topic of several analyst reports. The Goldman Sachs Group raised shares of TG Therapeutics from a “sell” rating to a “neutral” rating and dropped their price target for the stock from $16.00 to $12.00 in a research report on Wednesday, August 2nd. StockNews.com lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $41.00 price target on shares of TG Therapeutics in a research report on Monday, September 18th. Jefferies Financial Group reaffirmed a “buy” rating and set a $23.00 price target on shares of TG Therapeutics in a research report on Wednesday, November 1st. Finally, B. Riley dropped their price objective on shares of TG Therapeutics from $32.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, October 20th.
Institutional Investors Weigh In On TG Therapeutics
TG Therapeutics Stock Performance
Shares of TGTX stock opened at $12.82 on Thursday. The company’s fifty day simple moving average is $8.87 and its 200-day simple moving average is $16.60. The company has a quick ratio of 4.95, a current ratio of 5.53 and a debt-to-equity ratio of 0.60. The firm has a market cap of $1.94 billion, a PE ratio of -45.79 and a beta of 2.10. TG Therapeutics has a 12 month low of $6.46 and a 12 month high of $35.67.
TG Therapeutics (NASDAQ:TGTX – Get Free Report) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.44. TG Therapeutics had a negative net margin of 13.65% and a negative return on equity of 35.58%. The business had revenue of $165.80 million for the quarter, compared to analyst estimates of $23.91 million. During the same quarter in the previous year, the firm posted ($0.26) earnings per share. The firm’s revenue for the quarter was up 17538.3% on a year-over-year basis. Equities research analysts expect that TG Therapeutics will post 0.02 EPS for the current fiscal year.
About TG Therapeutics
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
- Five stocks we like better than TG Therapeutics
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- The most upgraded stocks in November have two things in common
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Monday.com rocked earnings like it’s the weekend
- 5 Top Rated Dividend Stocks to Consider
- Plan to own one retailer? Make it this one
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.